Deuruxolitinib: same daily dose, very different regrowth

Design

Phase 2 randomised trial, two active schedules, no placebo

Population

57 adults with severe alopecia areata (mean age 40.1 years, 66.7% female)

Primary outcome

Relative change from baseline in SALT score at week 24

Effect

8 mg twice daily 46.4 (90% CI 34.3 to 58.4) vs 16 mg once daily 18.0 (7.6 to 28.4)

Fifty-seven adults with severe alopecia areata were randomised to deuruxolitinib 8 mg twice daily or 16 mg once daily — the same 16 mg a day, split or not. At 24 weeks the mean relative change in Severity of Alopecia Tool score was 46.4 on the twice-daily schedule and 18.0 on the once-daily one, and more patients on twice-daily dosing reached SALT of 20 or below and 10 or below.

This is a phase 2 dose-optimisation study, not an efficacy trial: there is no placebo arm, so the size of the drug effect is not what is being measured. What it establishes is that the schedule, not the total daily dose, drives regrowth, which fits the short half-life of the molecule and the need for sustained JAK1/2 inhibition rather than a daily peak.

Treatment-emergent adverse events were mild or moderate. With 57 patients and no comparator, nothing can be said about the class risks — thrombosis, herpes zoster, lipid change — that determine whether this drug is suitable for a given patient.

• Where a JAK inhibitor with a short half-life is used, split dosing is the schedule these data support.
• SALT change is a continuous outcome; agree a target with the patient before starting.
• Baseline screening for tuberculosis, hepatitis, lipids and thrombotic risk applies to the whole class.
• Relapse after stopping is the rule in alopecia areata; plan the maintenance conversation at initiation.
• Note that 90 per cent confidence intervals were reported here, not 95 per cent — a phase 2 convention.

Why it matters

It shows that how often a JAK inhibitor is given can matter more than how much of it is given.

Don't overread it

Phase 2, 57 patients, no placebo arm — this establishes a schedule, not efficacy or safety.

The statistics, in plain English

The 90 per cent confidence intervals around the two means (34.3 to 58.4 and 7.6 to 28.4) do not overlap, which is the basis for preferring the split schedule; a 90 per cent interval is wider-tolerance than the 95 per cent used in confirmatory trials, so this is a signal to design around rather than a definitive comparison. With no placebo arm, neither number can be read as the effect of the drug.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.